Evidence map›Paper›PMID 24283768›Full record

Trial reportJournal of alternative and complementary medicine (New York, N.Y.)2014

Clinical efficacy of a West African sorghum bicolor-based traditional herbal preparation Jobelyn shows increased hemoglobin and CD4+ T-lymphocyte counts in HIV-positive patients.

Godwin I Ayuba, Gitte S Jensen, Kathleen F Benson, Ademola M Okubena, Olajuwon Okubena

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of alternative and complementary medicine (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02240173 (Phase 2 Study of the Antipsychotic Effects of Sorghum Bicolor), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02240173 phase1 / phase2unknown statusnot on this mapstarted 2017, after this paper: background citation

Phase 2 Study of the Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia.

TypeinterventionalSponsorFederal Neuro-Psychiatric Hospital, YabaRan2017 to 2017Enrolled100ConditionsSchizophrenia and Disorders With Psychotic FeaturesArmsJobelyn, Haloperidol
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. The Search for Drugs Derived from Natural Products forCurrent topics in medicinal chemistry · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Godwin I Ayuba1 Department of Pathology, 68 Nigerian Army Reference Hospital , Yaba, Lagos, Nigeria .
Gitte S Jensen
Kathleen F Benson
Ademola M Okubena
Olajuwon Okubena
Klamath Community College · USFederal Neuro Psychiatric Hospital · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe purpose of this study was to evaluate a traditional herbal preparation, Jobelyn,® for its effects on anemia and CD4+ T-cell counts in human immunodeficiency virus-positive (HIV+) patients in Nigeria.

designAn open-label pilot study involving 10 confirmed (HIV+) patients who were not receiving antiretroviral therapy (ARVT) was performed, in which the patients consumed Jobelyn for 8 weeks, at a dose of 500 mg twice daily. The pilot study was followed by a controlled trial involving 51 patients, all confirmed HIV+, where the patients with CD4+ T-cell counts below 350 cells/μL were receiving ARVT. The eight patients with baseline CD4+ T-cell counts above 350 cells/μL received Jobelyn. The remaining patients who all received ARVT were randomized to ARVT alone versus ARVT+Jobelyn for 12 weeks.

resultsPatients receiving ARVT showed a statistically significant improvement in their CD4+ T-cell counts across the 12-week study period (p<0.01). Patients receiving ARVT+Jobelyn showed a faster improvement, reaching a high level of statistical significance compared to baseline already at 6 weeks (p<0.001), and remained highly significant at 12 weeks (p<0.001).

conclusionsThis is the first controlled study conducted to evaluate efficacy of Jobelyn on immune status in HIV+ patients. The data suggest that consumption of Jobelyn contributed to improved hemoglobin levels and increased CD4+ T-cell counts in Nigerian HIV+ patients. Further studies are needed to examine similar effects in other populations, and to elaborate on the underlying mechanisms, specifically, whether the consumption of Jobelyn supported multiple aspects of bone marrow function.

Indexed as

CD4 Lymphocyte CountAdolescentAdultAgedAnti-Retroviral AgentsDietary SupplementsFemaleHemoglobinsHIV InfectionsHumansMaleMedicine, African TraditionalMiddle AgedNigeriaPilot ProjectsPlant PreparationsAnti-Retroviral AgentsHemoglobinsPlant Preparations

Identifiers

PMID24283768
PMCPMC3904510
OpenAlexW2111410908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.